An observational study in Veinous Access, Midline and Veinous Capital, sponsored by Centre Hospitalier de Valenciennes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Centre Hospitalier de Valenciennes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Venous access management plays a key role in patient care and preserving their venous capital. The so-called "conventional" peripheral venous catheter is the most common venous access device, but it is associated with a high rate of complications, particularly in cases of prolonged use or poor venous capital. Recommendations, such as those from MAGIC or SF2H, advocate their use when the intended duration of use is 5 days or less. For longer periods or in cases of difficult access, so-called "central" devices such as PICC lines or central venous catheters are used, although they present specific risks such as CLASBI or deep vein thrombosis.
In intermediate situations, the midline, a peripheral venous access device, is a relevant alternative, particularly for non-venotoxic intravenous treatments lasting more than 5 days. Although it is theoretically associated with fewer infections and complications than the PICCline, its complication rate and actual duration of use vary widely in the literature.
The MAGIC recommendations suggest using them for periods of 14 days or less. The widespread use of midlines in healthcare facilities, and in particular the creation of vascular access units, has given rise to issues shared between centers, notably the replacement rate of these devices. The study therefore aims to determine the replacement and early removal rates for midlines, the circumstances in which they are replaced, and toassess the relevance of the 28-day limit in the choice of device, in order to improve practices and optimize the practitioner's initial decision.
Centre Hospitalier de Valenciennes is the lead sponsor of 15 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients included in the study are those whose midline indication has been validated by the vascular access unit according to the hospital's organization. The expected duration of midline use should be 28 days or less.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evaluate the midline replacement rate regardless of the indication, in the various requesting centers
The primary endpoint is the cumulative incidence rate of midline replacement over a censored period of 28 days. This period begins on the day of inclusion with the first midline placement, regardless of the indication. Competing events are removal without replacement, regardless of the cause (death, removal at the end of treatment, early removal before the end of treatment without replacement).
Time frame: within 28 days after the initial placement of the midline
Secondary objective 1: To evaluate the early removal rate among patients living with midlines within 28 days of placement.
Cumulative incidence rate of early removal of midlines placed on the day of inclusion over a censored period of 28 days. Competing events are death and removal due to end of treatment
Time frame: over a censored period of 28 days
Secondary objective 2: Describe the reasons for early removal of midlines.
Midline removal rate for each of the following reasons: * Extravasation/diffusion of the product * Suspected midline infection * Confirmed midline infection * Accidental removal * Catheter-induced deep vein thrombosis * Catheter occlusion * Inability to perform sampling * Conversion to PICCline * Duration exceeded
Time frame: Withdrawals are analyzed from the day of inclusion and over a censored period of 28 days
Secondary objective 3: Describe the lifespan of midlines
Midline lifespan. The event is the removal of the midline regardless of the cause: removal at the end of treatment, removal due to death, early removal (with or without reinsertion).
Time frame: This duration includes the number of days between the day of inclusion and the day of device removal over a censored period of 28 days.
Secondary objective 4: Describe the replacement rate of midlines among midlines still in place at different time
Cumulative incidence rate of midline recurrence with a benchmark at D7, D14, then D21, censored at D28
Time frame: Days 7, 14, 21 and 28
Secondary objective 5: Compare the midline replacement rate between the initial indication of antibiotic therapy and the initial indication of insufficient venous capacity
Cumulative incidence rate of midline removal for the initial indication of antibiotic therapy and midline removal rate for the initial indication of insufficient venous access. The midlines analyzed are those placed on the day of inclusion. Concurrent events are removal without replacement regardless of the cause (death, removal at the end of treatment, early removal before the end of treatment without replacement).
Time frame: Replacements taken into account occur over a censored period of 28 days beginning on the day of inclusion
Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier de Valenciennes